Molecular Partners (NASDAQ:MOLN) Shares Down 0.5% – What’s Next?

Molecular Partners AG (NASDAQ:MOLN)’s share price traded down 0.5% during trading on Tuesday . The stock traded as low as $3.81 and last traded at $3.86. 13,897 shares were traded during mid-day trading, a decline of 29% from the average session volume of 19,646 shares. The stock had previously closed at $3.88.

Wall Street Analysts Forecast Growth

Separately, Lifesci Capital initiated coverage on shares of Molecular Partners in a research report on Tuesday, March 11th. They set an “outperform” rating and a $12.00 price objective for the company.

Molecular Partners Trading Down 0.5 %

The firm has a market capitalization of $155.85 million, a PE ratio of -1.80 and a beta of 1.06. The company has a fifty day moving average price of $4.74 and a two-hundred day moving average price of $5.15.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. As a group, equities research analysts predict that Molecular Partners AG will post -1.93 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Molecular Partners stock. Suvretta Capital Management LLC boosted its stake in Molecular Partners AG (NASDAQ:MOLN) by 455.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,221,494 shares of the company’s stock after acquiring an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned 5.50% of Molecular Partners worth $10,548,000 as of its most recent SEC filing. 26.55% of the stock is owned by institutional investors.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.